Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

149.65 +0.83 (+0.56%)
Streaming Delayed Price Updated: 3:39 PM EST, Jan 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 759,841
Open 148.92
Bid (Size) 149.56 (1)
Ask (Size) 149.74 (2)
Prev. Close 148.82
Today's Range 145.82 - 150.48
52wk Range 145.07 - 252.17
Shares Outstanding 144,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sage Therapeutics Stock Eyes Best Day In 5 Years On Biogen’s Unsolicited Bid: Retail Piles In
The two companies have collaborated since 2020 on the depression drug Zurzuvae, approved in 2023 by the FDA for treating postpartum depression. 
Via Stocktwits
Exposures Product Safety
Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy: Analysts
Biogen proposes acquiring Sage Therapeutics for $7.22 per share, as analysts highlight the strategic value of Zurzuvae's success in postpartum depression. 
Via Benzinga

Performance

YTD
-0.23%
-0.23%
1 Month
-0.25%
-0.25%
3 Month
-21.88%
-21.88%
6 Month
-32.46%
-32.46%
1 Year
-39.21%
-39.21%

More News

Read More
Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge
Via Benzinga
Exposures Fossil Fuels
Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday
Via Benzinga
Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?
Via Benzinga
Peering Into Biogen's Recent Short Interest
Via Benzinga
17 Analysts Assess Biogen: What You Need To Know
Via Benzinga
Assessing Biogen: Insights From 19 Financial Analysts
Via Benzinga
Enduring Truths for Investors Both New and Seasoned
Via The Motley Fool
Grid Expansion; Beaten Blues
Via Talk Markets
Topics Stocks / Equities
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected
Via Benzinga
Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet.
Via Investor's Business Daily
These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024
Via The Motley Fool
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
Via Benzinga
10 Worst Performing Large-Caps Last 12 Months
Via Talk Markets
Topics Stocks / Equities
Large-Cap Stocks In Trouble - Saturday, Dec. 21
Via Talk Markets
Topics Stocks / Equities
This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Via Benzinga
Super Micro Computer Teeters On Edge Of Nasdaq 100: Can xAI, Nvidia Help Stabilize Trajectory?
Via Benzinga
Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown
Via Benzinga
This AMD Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
These Are the 5 Worst-Performing Stocks in the Nasdaq-100 With 2024 Almost Over
Via The Motley Fool
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
Via Benzinga
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
From Biogen Inc.
Via GlobeNewswire
Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.